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Background: Deoxycytidine kinase (dCK) is responsible for the activation of several clinically important
deoxynucleoside analogues used for the treatment of haematological and solid malignancies.
Aim: To measure dCK expression in tumour cells from different origins.
Method: A rabbit antihuman dCK antibody was used for the immunocytochemical detection of dCK
expression in three leukaemic cell lines (HL60, U937, and CCRF-CEM) and 97 patient samples (paediatric
acute myeloid leukaemia (AML) and lymphoid leukaemia (ALL), retinoblastoma, paediatric brain tumours,
and adult non-small cell lung cancer (NSCLC)).
Results: CCRF-CEM, U937, and HL60 cells stained positively for dCK and the degree of expression
correlated with dCK activity. dCK expression varied between tumour types and between individual patients
within one tumour type. dCK was located predominantly in the cytoplasm. The staining intensity was
scored as negative (0), low (1+), intermediate (2+), or high (3+). Expression of dCK was high in AML
blasts. In contrast, brain tumour samples expressed low amounts of dCK. dCK staining ranged from low
(1+) to high (3+) in ALL blasts, retinoblastoma, and NSCLC tissue samples. Staining was consistent
(interobserver variability, 88%; k = 0.83) and specific. Western blotting detected the dCK protein
appropriately at 30 kDa, without additional bands.
Conclusions: Immunocytochemistry is an effective and reliable method for determining the expression of
dCK in patient samples and requires little tumour material. This method enables large scale screening of
dCK expression in tumour samples.
D
eoxycytidine kinase (dCK) phosphorylates 29-deoxycy-
tidine to its monophosphate form, which is the rate
limiting step in deoxynucleoside salvage.1–3 dCK is
also required for activation of several clinically important
deoxynucleoside analogues.4 5 These include the classic
deoxycytidine analogues cytarabine (ara-C) and 5-aza-
29deoxycytidine, in addition to the purine analogues cladri-
bine and fludarabine, which are widely used for the
treatment of childhood and adult leukaemia. Several novel
deoxynucleoside analogues with activity in solid tumours (for
example, gemcitabine and troxacitabine) also require activa-
tion by dCK.6 7 Resistance to deoxynucleoside analogues in
cell lines has been linked to dCK deficiency.8–13 Transfection
and induction of dCK restored sensitivity to ara-C and
gemcitabine.14 Furthermore, a strong correlation between the
antitumour effect of gemcitabine and dCK activity has been
observed.15
‘‘Resistance to deoxynucleoside analogues in cell lines has
been linked to deoxycytidine kinase deficiency’’
The dCK gene is localised on chromosome 4.16–18 Human
dCK functions as a homodimer of 60 kDa, consisting of two
identical 30.5 kDa subunits.17 dCK is expressed in a con-
stitutive manner throughout the cell cycle,2 19 20 and is
expressed predominantly in lymphoid tissues, indicating cell
type specific regulation.16 17 21 22 Moreover, dCK expression
can be upregulated in certain malignancies.23 The molecular
mechanism leading to tissue specific transcription of dCK has
not yet been elucidated. Another level of control could
involve regulation of the subcellular localisation of the
enzyme. dCK has been described as a cytoplasmic protein,
but when overexpressed in vitro it was localised mainly in the
nucleus.19 24
We have established an immunocytochemical staining
method for the detection of dCK, using a rabbit antihuman
dCK antibody directed against the C-terminal end of the dCK
protein. Immunocytochemical detection could be a valuable
tool for pretreatment screening of dCK values in malignan-
cies to be treated with deoxynucleoside analogues, because it
requires only a small number of tumour cells, and cellular
morphology is maintained, allowing studies on the subcel-
lular localisation of dCK. In our present study, we describe
the methodology of immunocytochemical staining for dCK in
cell lines and patient samples from different tumour types,
including childhood acute myeloid leukaemia (AML), child-
hood acute lymphoblastic leukaemia (ALL), and adult non-
small cell lung cancer (NSCLC). Some paediatric retinoblas-
toma and brain tumour (peripheral neural ectodermal
tumour and ependymoma) samples were included in our
Table 1 Deoxycytidine kinase (dCK) activity in
leukaemic cell lines
Cell line dCK activity (nmol/hr/mg protein)
HL60 31.9 (4.9)
CCRF-CEM 22.7 (2.4)
U937 14.1 (2.2)
Values are the mean (SE) of three experiments.
Abbreviations: ALL, acute lymphoid leukaemia; AML, acute myeloid
leukaemia; ara-C, cytarabine; dCK, deoxycytidine kinase; NSCLC, non-
small cell lung cancer; PBS, phosphate buffered saline
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analyses for comparative purposes, because they are extre-
mely resistant to ara-C in vitro, possibly as a result of a
deficiency in dCK.25 26
MATERIALS AND METHODS
Cell l ines
The leukaemic cell lines HL60, U937, and CCRF-CEM were
cultured as described previously.27 Cytospin preparations
were made with 50 ml cell suspensions (0.56 106 cells/ml
in phosphate buffered saline (PBS) containing 5% human
serum albumin). Cytospins were air dried on silica gel for at
least 48 hours and subsequently stored at –20 C˚.
Leukaemic samples
Bone marrow or peripheral blood samples taken for routine
diagnostic purposes were obtained with informed consent
and institutional review board approval from 31 children
with de novo AML and 29 children with de novo ALL.
Mononuclear cells were separated by density gradient
centrifugation (Lymphoprep; density 1.077 g/ml; Nycomed
Pharma, Oslo, Norway). Where necessary, the proportion of
malignant cells was enriched, as described previously,28 after
which the percentage of leukaemic cells was determined
morphologically (May-Gru¨nwald-Giemsa staining; Merck,
Darmstadt, Germany) and cytospins were prepared.
Solid tumours
Primary tumour material was collected with informed
consent and institutional review board approval from 12
children diagnosed with a brain tumour (peripheral neural
ectodermal tumour (n = 7) or ependymoma (n = 5)) and
from 10 patients with retinoblastoma. Tumour samples were
collected fresh and under sterile conditions in PBS containing
100 IU/ml penicillin, 100 mg/ml streptomycin, and 0.125 mg/
ml amphotericin (Gibco BRL, Breda, The Netherlands). Cell
suspensions were made as described previously.25 26 The
viability of the cells was determined by trypan blue exclusion.
The final percentage of malignant cells was assessed by May-
Gru¨nwald-Giemsa staining and cytospin preparations were
made.25 Formalin fixed, paraffin wax embedded tumour
samples from 15 patients with NSCLC were evaluated. Tissue
sections were cut into 4 mm thick sections and mounted on
poly-L-lysine coated slides. Slides were stored at room
temperature.
Immunocytochemical and histochemical staining
Cryopreserved cytospins were thawed at room temperature
(30 minutes). All incubations were performed at room
temperature. Cells were fixed using 10% formaldehyde (20
minutes). Endogenous myeloperoxidase was inactivated with
PBS/1% H2O2 for 10 minutes. Slides were washed (PBS,
36 10 minutes) and blocked (10% normal swine serum; 30
minutes; Sigma, St Louis, Missouri, USA). Slides were
incubated with the primary antibody, a rabbit polyclonal
anti-dCK antibody,24 diluted 1/200 in 1% bovine serum
albumin/10% pooled human serum/PBS (two hours). After
PBS wash steps, the secondary antibody, biotinylated swine
antirabbit (1/300 dilution in PBS/1% bovine serum albumin/
2% pooled human serum, 30 minutes; Dako, Glostrup,
Denmark) was applied. Slides were rinsed (PBS) and
incubated with horseradish peroxidase conjugated streptavi-
din (1/100 dilution in PBS/1% bovine serum albumin, 45
minutes; Dako). Peroxidase activity was determined using
1mM 3,39diaminobenzidine (Sigma), 0.05M imidazole
(Merck), and 0.036% H2O2 in 0.05M Tris buffer (pH 7.4)
for 10 minutes. Cells were counterstained using Mayer’s
haematoxylin solution (Merck) and embedded in malinol.
CCRF-CEM cells were used as a positive control in each
experiment. Negative controls were performed for each
sample by omitting the primary antibody. The staining was
examined by light microscopy. dCK protein expression was
determined by scoring the intensity of the staining: negative
(0), low (1+), intermediate (2+), or high (3+), by two
observers (IH and AJFB) in independent sessions, without
knowledge of each others results.
NSCLC tissue sections were dewaxed and rehydrated by
incubation in 100% xylene (26 10 minutes), followed by
incubation in decreasing ethanol concentrations. Sections
were fixed and endogenous myeloperoxidase was blocked
(methanol/0.3% H2O2; 30 minutes). Antigen retrieval was
performed by heating the slides in a microwave for 15
minutes in 10mM citrate buffer solution (pH 6.0). Slides
Figure 1 Immunocytochemical staining of deoxycytidine kinase in the leukaemic cell lines. (A) U937 phosphate buffered saline negative control, (B)
U937, (C) CCRF-CEM, and (D) HL60.
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were cooled down at room temperature for at least 30
minutes and washed (PBS). Non-specific staining was
blocked using normal swine serum (1/10 dilution; 10
minutes). The remainder of the protocol was performed as
described above.
dCK activity assay
dCK activity was determined using 3H-chlorodeoxyadenosine
as a substrate (final concentration 50mM; specific activity,
0.19 mCi/nmol) with 5mM MgATP as phosphate donor and
100mM NaF to prevent nucleotide breakdown, as described
in detail previously.27 Enzyme activity was expressed as nmol
3H-chlorodeoxyadenosine monophosphate formed/hour/mg
protein.
Immunoblotting
To determine the specificity of the antibody, immunoblotting
was carried out on two leukaemic cell lines (U937 and HL60)
and two AML patient samples. Western blotting was
performed as described previously by electrophoresis on
12.5% sodium dodecyl sulfate polyacrylamide gels and
transfer by electroblotting to nitrocellulose membranes.27
Purified dCK protein with a histidine tag was used as a
positive control. Blocking was performed with blocking
buffer (5% non-fat dry milk blocking grade in PBS/0.1%
Tween 20 for one hour) and the blot was probed with rabbit
antihuman dCK polyclonal antibody (1/5000 dilution; one
hour at room temperature) and goat antirabbit secondary
antibody conjugated to horseradish peroxidase (1/3000
dilution; one hour at room temperature (Santa Cruz Bio-
technology, Santa Cruz, California, USA)). Peroxidase activ-
ity was visualised using the enhanced chemiluminescence
(ECL) kit (Amersham Biosciences, Little Chalfont,
Buckinghamshire, UK).
Statistics
The k statistic was used to assess agreement between
observers.29 Otherwise the data analysis was merely descrip-
tive.
Figure 2 Immunocytochemical
staining of deoxycytidine kinase (dCK)
in patient samples from different tumour
types. (A) An acute myeloid leukaemia
sample and (B) a retinoblastoma
sample with strong expression of dCK
(3+). (C) An acute lymphoid leukaemia
sample with weak staining (1+); (D) A
brain tumour sample negative for dCK
(0). Non-small cell lung cancer tissue
stained for dCK: (E) phosphate buffered
saline negative control and (F) a sample
with high dCK expression (3+)
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Figure 3 Expression of the deoxycytidine kinase (dCK) protein in
different tumour types. The acute myeloid leukaemia (AML) and
retinoblastoma samples showed high expression of dCK (predominantly
3+). In contrast, the brain tumour samples showed low expression of
dCK (0–2+) and in acute lymphoid leukaemia (ALL) samples dCK
expression was intermediate (2+). NSCLC, non-small cell lung cancer.
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RESULTS
Immunocytochemistry and histochemistry
Titration of the primary antibody between 1/50 and 1/1000
resulted in optimal staining when a concentration of 1/200
was used. Optimal fixation of cytospins was with 10%
formaldehyde. Other fixatives (such as methanol, 4%
paraformaldehyde, or acetone) resulted in non-evaluable
samples. Good cellular morphology was crucial because
cytospins of poor quality resulted in non-evaluable stainings.
Negative controls did not stain. HL60, CCRF-CEM, and U937
cells stained positive for dCK, but to different degrees (fig 1).
Staining was strongest in the HL60 cells, which also showed
nuclear staining, and lowest in U937. In CCRF-CEM and
U937 cells dCK was located exclusively in the cytoplasm.
Immunocytochemistry and western blotting data were in
agreement with dCK activity (table 1). In clinical samples,
CCRF-CEM served as a positive control and gave similar
staining results in each experiment.
In all tumour samples, expression varied and a predomi-
nantly cytoplasmic staining was seen (figs 2, 3). Nuclear
staining was also seen in four of 31 AML samples and in two
of 29 ALL samples. Expression of dCK was either inter-
mediate (2+) or strong (3+) in AML blasts, but in ALL,
retinoblastoma, and NSCLC expression ranged from low (1+)
to high (3+). Staining for dCK was weak (1+) or intermediate
(2+) in brain tumours. dCK was not detectable in two brain
tumour samples. The reproducibility of staining was tested by
replicate staining of 10 patient samples and was found to be
good (80%). The interobserver variability was low: in 72 of 82
cases the first observation was in agreement (k = 0.83);
disagreement only involved scores of 2+/3+ (intermediate/
high). At re-examination by both observers agreement was
reached, and this consensus was used in the final analysis.
Western blotting
Western blotting was performed on two cell lines and two
AML patient samples to evaluate the specificity of the
antibody (fig 4). The band for dCK was located at 30 kDa,
as expected, and no bands were seen at 60 kDa. The purified
dCK-his protein was clearly visible. No additional bands were
seen on the blots, indicating high specificity for dCK in both
the leukaemic cell lines and patient samples.
DISCUSSION
We describe the immunocytochemical staining of dCK with a
rabbit polyclonal antibody. This method is rapid, reproduci-
ble, and can be used to evaluate dCK expression in different
malignancies. Although various antibodies against dCK have
been described and used for western blotting, immunocy-
tochemistry of patient samples has not been reported
previously.19 23 24 The antibody was highly specific on both
western blotting and immunocytochemistry. The specificity
of this antibody was tested earlier and found to be blocked by
the same recombinant dCK used as a control in fig 4.24 The
interobserver variability was good. In patient samples, it was
possible to discriminate between negative, low, intermediate,
and high expression of dCK. There were clear differences
between tumour types. In most samples, dCK was located
exclusively in the cytoplasm, which is in agreement with
previous studies that also describe dCK as a cytoplasmic
enzyme.2 18 However, a study by Johansson et al reported that
dCK can be found in the nucleus and that the N-terminal
region (amino acids, 6–23) of the dCK protein contains a
nuclear import signal.19 Hatzis et al showed that dCK is
predominantly located in the cytoplasm in several cell types,
but when overexpressed it was mainly located in the
nucleus.24 Our study shows that nuclear localisation can be
seen in several AML and ALL samples with high dCK
expression. Nuclear staining was never seen in samples with
a low or intermediate degree of dCK expression.
Retinoblastomas showed positive staining, although they
are highly resistant to ara-C in vitro.25 30 The presence of a
mutation in the retinoblastoma tumour suppressor gene,
characteristic for this disease, possibly encodes for general
drug resistance. Brain tumour samples, which are also very
resistant to ara-C in vitro,26 showed weak dCK staining.
Therefore, dCK expression might play a role in ara-C
resistance in this tumour type.
‘‘Brain tumour samples, which are very resistant to
cytarabine in vitro, showed weak deoxycytidine kinase
staining’’
The patients with AML included in our study were all
treated with ara-C containing protocols. Unfortunately, we
were not able to assess the relation between dCK protein
expression and in vivo response to treatment because of the
heterogeneity of the treatment received. Patients were treated
according to different treatment regimens and several
different dosing schedules. However, we are currently
assessing the relation between dCK protein expression and
in vitro ara-C sensitivity. In addition, we are using
immunocytochemistry to screen a large group of samples
from patients with NSCLC, who have been treated with
gemcitabine, for pretreatment dCK expression and its
relation to in vivo response.
Our study shows that immunocytochemistry is an effective
method to determine the degree of expression of dCK in
patient samples, and only requires a small amount of tumour
material. This will enable the evaluation of dCK expression as
a predictor of initial response to treatment and final outcome.
HL60
30 kDa
dCK-his U937
AML patient
sample 1
AML patient
sample 2
Figure 4 Western blot using the anti-deoxycytidine kinase (dCK)
antibody (1/5000 dilution) on the leukaemic cell lines HL60 and U937,
purified dCK protein (dCK-his), and two AML patient samples. Samples
(20 mg protein) were loaded in duplicate and b actin was used for
normalisation. The band for dCK was located at 30 kDa, as expected.
The purified dCK protein band was located slightly higher because of the
histidine tag. No additional bands were seen. The intensity of the band
for the CCRF-CEM cells was intermediate, as described previously.27
Take home messages
N We measured the immunohistochemical expression of
deoxycytidine kinase (dCK), which is responsible for
the activation of several clinically important deoxynu-
cleoside analogues used for the treatment of haema-
tological and solid malignancies, in several cell lines
and tumour types
N Immunocytochemistry was found to be an effective and
reliable method for determining the expression of dCK
in patient samples and required little tumour material
N The use of this method will enable the evaluation of
dCK expression as a predictor of initial response to
treatment and final outcome
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